Hematologic Oncology Update

47:06

Diffuse Large B-Cell Lymphoma — An Interview with Dr...

Hematologic Oncology Update ·

2026/10/05

Featuring an interview with Dr L Elizabeth Budde, including the following topics:Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and

en

50:22

Diffuse Large B-Cell Lymphoma — Proceedings from a...

Hematologic Oncology Update ·

2026/10/01

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications

en

54:25

Chronic Lymphocytic Leukemia — Proceedings from a...

Hematologic Oncology Update ·

2026/09/28

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications

en

01:28:21

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia...

Hematologic Oncology Update ·

2026/09/25

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications

en

49:41

Antibody-Drug Conjugates for Multiple Myeloma — An...

Hematologic Oncology Update ·

2026/09/23

Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)Progression-free survival estimates with current quadruplet induction and

en

59:49

Chronic Myeloid Leukemia — An Interview with Prof...

Hematologic Oncology Update ·

2026/09/12

Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (10:23)Recent survey of patients with CML regarding goals of therapy and clinical implications;

en

30:54

Chronic Lymphocytic Leukemia — Rapid Case Review:...

Hematologic Oncology Update ·

2026/09/07

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)Case: A man in his

en

22:58

Chronic Lymphocytic Leukemia — 5-Minute Journal Club:...

Hematologic Oncology Update ·

2026/09/06

Featuring perspectives from Prof John Seymour, including the following topics:Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)CME information and select publications

en

58:40

Relapsed/Refractory Chronic Lymphocytic Leukemia — A...

Hematologic Oncology Update ·

2026/09/02

Featuring perspectives from Dr William G Wierda, including the following topics:Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — Pirtobrutinib (21:08)Investigator Survey (34:09)Chimeric Antigen Receptor T-Cell Therapy (45:08)Other Novel Therapy Approaches (49:58)EHA 2026 (54:45)CME information and select publications

en

01:00:04

Non-Hodgkin Lymphoma — Year in Review Series on...

Hematologic Oncology Update ·

2026/08/26

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)CME information and select publications

en

57:45

Multiple Myeloma — Year in Review Series on Relevant...

Hematologic Oncology Update ·

2026/08/17

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)ASCO and EHA 2026 (46:37)CME information and select publications

en

01:59:30

Non-Hodgkin Lymphoma — Proceedings from a Session...

Hematologic Oncology Update ·

2026/08/13

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:Introduction (0:00)Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma

en

57:46

Myelofibrosis — Proceedings from a Webinar Held in...

Hematologic Oncology Update ·

2026/08/11

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:Introduction (0:00)The Biopathophysiology of Myelofibrosis (MF) (2:19)Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)Upcoming at European Hematology Association (EHA) 2026 (49:22)CME information and select publications

en

02:00:04

Chronic Lymphocytic Leukemia — Proceedings from a...

Hematologic Oncology Update ·

2026/08/05

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:Introduction (0:00)Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)Optimal Management of Adverse Events with BTK

en

01:26:43

For Oncology Nurses: Relapsed/Refractory Multiple...

Hematologic Oncology Update ·

2026/08/03

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:Introduction (00:00)Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)Utility of Belantamab Mafodotin in R/R MM (49:29)Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)CME information and select publications

en

22:17

Chronic Lymphocytic Leukemia — 5-Minute Journal Club:...

Hematologic Oncology Update ·

2026/07/27

Featuring perspectives from Dr Mazyar Shadman, including the following topics:The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)Zanubrutinib-based therapy for treatment-naïve CLL (12:32)CME information and select publications

en

29:33

Chronic Lymphocytic Leukemia — Rapid Case Review:...

Hematologic Oncology Update ·

2026/07/27

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives

en

01:57:32

Relapsed/Refractory Multiple Myeloma — Proceedings...

Hematologic Oncology Update ·

2026/07/22

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:Introduction (0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)Chimeric Antigen Receptor T-Cell Therapy for R/R

en

01:58:26

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic...

Hematologic Oncology Update ·

2026/07/16

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone

en

01:57:14

Novel Therapies for Non-Hodgkin Lymphoma —...

Hematologic Oncology Update ·

2026/07/09

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)Optimal Use of

en

All Episodes

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media